JPMorgan upgraded Zymeworks (ZYME) to Overweight from Neutral with a price target of $18, up from $12 following last week’s research and development day. The firm left the event more confident in the company’s oncology and autoimmune diseases pipeline. With partnered Ziihera “providing a solid support to the valuation, 2025 is the year investors should pay attention for Zymeworks, the analyst tells investors in a research note. The firm says the company could begin to see one or more of its “5×5” plan succeeding in the clinics.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ZYME:
- Zymeworks upgraded to Overweight from Neutral at JPMorgan
- Zymeworks Advances Oncology and Expands Therapeutic Reach
- Zymeworks hosts R&D day highlighting continued clinical progress
- Zymeworks to Showcase Innovations at Investor Conferences
- Zymeworks Secures FDA Approval for Ziihera
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
